Balchem Corporation Reports Third Quarter Sales of $244.3 Million, Net Earnings of $25.2 Million, GAAP EPS of $0.78, and Adjusted EPS of $1.00
Balchem Corporation (NASDAQ: BCPC) reported a net earnings increase to $25.2 million for Q3 2022, compared to $25.0 million in Q3 2021. Adjusted net earnings rose to $32.4 million, up 8% year-over-year, with adjusted EBITDA at $53.8 million, reflecting an 11.2% increase.
Net sales reached $244.3 million, a 23.4% increase driven by growth in all segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products. The effective tax rate declined to 18.8%. Cash flows from operations were $41.6 million, with free cash flow at $26.8 million.
- Net sales increased by 23.4% to $244.3 million.
- Adjusted net earnings rose 8% to $32.4 million.
- Adjusted EBITDA increased 11.2% to $53.8 million.
- Human Nutrition & Health segment saw sales growth of 28.3%.
- Acquisition of Bergstrom enhances product offerings.
- Gross margin decreased to 28.0%, down 278 basis points.
- Operating expenses rose to $34.8 million, impacted by acquisitions.
MONTVALE, N.J., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ: BCPC) reported today third quarter net earnings of
Third Quarter 2022 Financial Highlights:
- Net sales were
$244.3 million , an increase of$46.4 million , or23.4% , compared to the prior year quarter, with sales growth in all three segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products.
- Adjusted EBITDA was
$53.8 million , an increase of$5.4 million , or11.2% , from the prior year.
- GAAP net earnings were
$25.2 million , an increase of$0.2 million , or0.9% from the prior year. These net earnings resulted in GAAP earnings per share of$0.78 .
- Adjusted net earnings were
$32.4 million , an increase of$2.4 million or8.0% from the prior year. These adjusted net earnings resulted in adjusted earnings per share(a) of$1.00 .
- The effective tax rate of
18.8% was 327 basis points lower than the prior year tax rate of22.0% .
- Cash flows from operations were
$41.6 million for the third quarter 2022, with quarterly free cash flow(a) of$26.8 million .
Recent Highlights:
- On August 30, 2022, we completed the acquisition of Cardinal Associates Inc. and its Bergstrom Nutrition business (collectively, "Bergstrom"), a leading science-based manufacturer of methylsulfonylmethane (MSM), based in Vancouver, Washington. MSM is a widely used ingredient with strong scientific evidence supporting its benefits for joint health, sports nutrition, skin and beauty, healthy aging, and pet health. Bergstrom's MSM brand "OptiMSM®" delivers the highest quality and purity MSM on the market and is the only brand of MSM with a U.S. GRAS "generally regarded as safe" designation.
- Balchem's VitaCholine® brand recently won NutraIngredients USA's prestigious Nutra Award for Ingredient of the Year - Cognitive Function. VitaCholine® is the premier source of choline, an essential nutrient that supports cognition and brain development in children. A clinical study recently published by Cornell University researchers showed significant brain benefits for babies born to mothers who received higher levels of supplemental choline during pregnancy.
- We made repayments on our revolving debt in the third quarter of
$41.0 million . Net debt was$406.1 million , with an overall leverage ratio on a net debt basis of 1.9.
Ted Harris, Chairman, President and CEO of Balchem said, “The third quarter of 2022 was another solid growth quarter for Balchem as we delivered both sales and earnings growth year over year in an increasingly challenging macro-economic environment. Additionally, we were very pleased to have further accelerated our strategic initiatives, highlighted by the acquisition of Bergstrom. This acquisition adds to our science based health and nutrition product offering for our Human Nutrition and Health segment and our Animal Nutrition and Health segment, and is synergistic with our existing organic growth platforms.”
Mr. Harris added, “I would like to take this opportunity to thank all of our employees for their contributions to our strong performance and for their continued dedication and focus on driving results in a unique and challenging market environment, while also welcoming once again the Bergstrom team to Balchem."
Results for Period Ended September 30, 2022 (unaudited)
(Dollars in thousands, except per share data)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||
| Net sales | $ | 244,267 | $ | 197,869 | $ | 709,827 | $ | 585,890 | ||||
| Gross margin | 68,430 | 60,934 | 211,812 | 179,108 | ||||||||
| Operating expenses | 34,805 | 28,421 | 99,931 | 85,427 | ||||||||
| Earnings from operations | 33,625 | 32,513 | 111,881 | 93,681 | ||||||||
| Other expense | 2,540 | 428 | 3,908 | 1,594 | ||||||||
| Earnings before income tax expense | 31,085 | 32,085 | 107,973 | 92,087 | ||||||||
| Income tax expense | 5,836 | 7,072 | 24,012 | 20,932 | ||||||||
| Net earnings | $ | 25,249 | $ | 25,013 | $ | 83,961 | $ | 71,155 | ||||
| Diluted net earnings per common share | $ | 0.78 | $ | 0.77 | $ | 2.59 | $ | 2.18 | ||||
| Adjusted EBITDA(a) | $ | 53,774 | $ | 48,344 | $ | 163,815 | $ | 144,213 | ||||
| Adjusted net earnings(a) | $ | 32,387 | $ | 29,975 | $ | 100,191 | $ | 88,819 | ||||
| Adjusted net earnings per common share(a) | $ | 1.00 | $ | 0.92 | $ | 3.09 | $ | 2.72 | ||||
| Shares used in the calculations of diluted and adjusted net earnings per common share | 32,367 | 32,644 | 32,392 | 32,651 | ||||||||
| (a) | See “Non-GAAP Financial Information” for a reconciliation of GAAP and non-GAAP financial measures. |
Financial Results for the Third Quarter of 2022:
The Human Nutrition & Health segment generated quarterly sales of
The Animal Nutrition & Health segment generated quarterly sales of
The Specialty Products segment generated quarterly sales of
Consolidated gross margin for the quarter ended September 30, 2022 of
Interest expenses were
For the quarter ended September 30, 2022, cash flows provided by operating activities were
Ted Harris said, “I am very pleased with how the Balchem team continues to manage through the current market conditions, and how we have shown resilience and the ability to deliver strong results, even in challenging times. We remain excited about our future and our ability to provide solutions for the health and nutritional needs of the world while acting as strong stewards of all of our stakeholders.”
Quarterly Conference Call
A quarterly conference call will be held on Friday, November 4, 2022, at 11:00 AM Eastern Time (ET) to review third quarter 2022 results. Ted Harris, Chairman, President and CEO and Martin Bengtsson, CFO will host the call. We invite you to listen to the conference by calling toll-free 1-877-407-8289 (local dial-in 1-201-689-8341), five minutes prior to the scheduled start time of the conference call. The conference call will be available for replay two hours after the conclusion of the call through end of day Friday, November 18, 2022. To access the replay of the conference call, dial 1-877-660-6853 (local dial-in 1-201-612-7415), and use conference ID #13733850.
Segment Information
Balchem Corporation reports three business segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products. The Human Nutrition & Health segment delivers customized food and beverage ingredient systems, as well as key nutrients into a variety of applications across the food, supplement and pharmaceutical industries. The Animal Nutrition & Health segment manufactures and supplies products to numerous animal health markets. Through Specialty Products, Balchem provides specialty-packaged chemicals for use in healthcare and other industries, and also provides chelated minerals to the micronutrient agricultural market. Sales and production of products outside of our reportable segments and other minor business activities are included in "Other and Unallocated".
Forward-Looking Statements
This release contains forward-looking statements, which reflect Balchem’s expectation or belief concerning future events that involve risks and uncertainties. Balchem can give no assurance that the expectations reflected in forward-looking statements will prove correct and various factors could cause results to differ materially from Balchem’s expectations, including risks and factors identified in Balchem’s annual report on Form 10-K for the year ended December 31, 2021 and Form 10-Q for the quarterly period ended June 30, 2022. Forward-looking statements are qualified in their entirety by the above cautionary statement. Balchem assumes no duty to update its outlook or other forward-looking statements as of any future date.
Contact: Jacqueline Yarmolowicz, Balchem Corporation (Telephone: 845-326-5600)
Selected Financial Data (unaudited)
($ in 000’s)
| Business Segment Net Sales: | Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| Human Nutrition & Health | $ | 142,655 | $ | 111,200 | $ | 396,728 | $ | 327,187 | ||||||||
| Animal Nutrition & Health | 65,604 | 56,192 | 197,546 | 161,821 | ||||||||||||
| Specialty Products | 29,641 | 27,615 | 99,622 | 89,645 | ||||||||||||
| Other and Unallocated (b) | 6,367 | 2,862 | 15,931 | 7,237 | ||||||||||||
| Total | $ | 244,267 | $ | 197,869 | $ | 709,827 | $ | 585,890 | ||||||||
| Business Segment Earnings Before Income Taxes: | Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| Human Nutrition & Health | $ | 20,584 | $ | 19,801 | $ | 64,592 | $ | 58,512 | ||||||||
| Animal Nutrition & Health | 8,036 | 7,442 | 26,943 | 16,059 | ||||||||||||
| Specialty Products | 7,105 | 6,455 | 24,785 | 23,373 | ||||||||||||
| Other and Unallocated (b) | (2,100 | ) | (1,185 | ) | (4,439 | ) | (4,263 | ) | ||||||||
| Interest and other expense | (2,540 | ) | (428 | ) | (3,908 | ) | (1,594 | ) | ||||||||
| Total | $ | 31,085 | $ | 32,085 | $ | 107,973 | $ | 92,087 | ||||||||
| (b) Other and Unallocated consists of a few minor businesses which individually do not meet the quantitative thresholds for separate presentation and corporate expenses that have not been allocated to a segment. Unallocated corporate expenses consist of: (i) Transaction and integration costs, ERP implementation costs, and unallocated legal fees totaling | ||||||||||||||||
| Selected Balance Sheet Items | ||||||||
| (Dollars in thousands) | September 30, 2022 | December 31, 2021 | ||||||
| (unaudited) | ||||||||
| Cash and Cash Equivalents | $ | 56,489 | $ | 103,239 | ||||
| Accounts Receivable, net | 140,812 | 117,408 | ||||||
| Inventories | 139,464 | 91,058 | ||||||
| Derivative Assets | 14,540 | — | ||||||
| Other Current Assets | 16,806 | 10,527 | ||||||
| Total Current Assets | 368,111 | 322,232 | ||||||
| Property, Plant & Equipment, net | 260,008 | 237,517 | ||||||
| Goodwill | 749,035 | 523,949 | ||||||
| Intangible Assets with Finite Lives, net | 227,323 | 94,665 | ||||||
| Right of Use Assets | 13,819 | 9,288 | ||||||
| Other Assets | 14,712 | 11,674 | ||||||
| Total Assets | $ | 1,633,008 | $ | 1,199,325 | ||||
| Current Liabilities | $ | 142,085 | $ | 143,802 | ||||
| Revolving Loan | 462,569 | 108,569 | ||||||
| Deferred Income Taxes | 76,771 | 46,455 | ||||||
| Derivative Liabilities | — | 2,658 | ||||||
| Contingent Consideration Liabilities | 30,547 | — | ||||||
| Other Long-Term Obligations | 25,114 | 20,826 | ||||||
| Total Liabilities | 737,086 | 322,310 | ||||||
| Stockholders' Equity | 895,922 | 877,015 | ||||||
| Total Liabilities and Stockholders' Equity | $ | 1,633,008 | $ | 1,199,325 | ||||
Balchem Corporation
Condensed Consolidated Statements of Cash Flows
(Dollars in thousands)
(unaudited)
| Nine Months Ended September 30, | ||||||||
| 2022 | 2021 | |||||||
| Cash flows from operating activities: | ||||||||
| Net earnings | $ | 83,961 | $ | 71,155 | ||||
| Adjustments to reconcile net earnings to net cash provided by operating activities: | ||||||||
| Depreciation and amortization | 37,958 | 36,622 | ||||||
| Stock compensation expense | 9,838 | 8,809 | ||||||
| Other adjustments | 912 | (2,231 | ) | |||||
| Changes in assets and liabilities | (35,788 | ) | 1,668 | |||||
| Net cash provided by operating activities | 96,881 | 116,023 | ||||||
| Cash flows from investing activities: | ||||||||
| Cash paid for acquisition, net of cash acquired | (365,780 | ) | — | |||||
| Capital expenditures and intangible assets acquired | (35,793 | ) | (22,391 | ) | ||||
| Proceeds from insurance and sale of assets | 198 | 1,272 | ||||||
| Purchase of convertible note | (150 | ) | — | |||||
| Net cash used in investing activities | (401,525 | ) | (21,119 | ) | ||||
| Cash flows from financing activities: | ||||||||
| Proceeds from revolving loan | 435,000 | 5,000 | ||||||
| Principal payments on revolving loan | (81,000 | ) | (60,000 | ) | ||||
| Principal payments on acquired debt | (30,782 | ) | — | |||||
| Cash paid for financing costs | (1,232 | ) | — | |||||
| Principal payments on finance lease | (125 | ) | (118 | ) | ||||
| Proceeds from stock options exercised | 2,172 | 6,351 | ||||||
| Dividends paid | (20,708 | ) | (18,704 | ) | ||||
| Purchase of treasury stock | (35,245 | ) | (18,762 | ) | ||||
| Net cash provided by (used in) financing activities | 268,080 | (86,233 | ) | |||||
| Effect of exchange rate changes on cash | (10,186 | ) | (3,229 | ) | ||||
| (Decrease) increase in cash and cash equivalents | (46,750 | ) | 5,442 | |||||
| Cash and cash equivalents, beginning of period | 103,239 | 84,571 | ||||||
| Cash and cash equivalents, end of period | $ | 56,489 | $ | 90,013 | ||||
Non-GAAP Financial Information
In addition to disclosing financial results in accordance with United States (U.S.) generally accepted accounting principles (GAAP), this earnings release contains non-GAAP financial measures that we believe are helpful in understanding and comparing our past financial performance and our future results. The non-GAAP financial measures in this press release include adjusted gross margin, adjusted earnings from operations, adjusted net earnings and the related adjusted per diluted share amounts, EBITDA, adjusted EBITDA, adjusted income tax expense, and free cash flow. The non-GAAP financial measures disclosed by the company exclude certain business combination accounting adjustments and certain other items related to acquisitions, certain equity compensation, and certain one-time or unusual transactions. Detailed non-GAAP adjustments are described in the reconciliation tables below and also explained in the related footnotes. These non-GAAP financial measures should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP, and the financial results calculated in accordance with GAAP and reconciliations from these results should be carefully evaluated. Investors should not consider non-GAAP measures as alternatives to the related GAAP measures.
Set forth below are reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures.
Table 1
Reconciliation of Non-GAAP Measures to GAAP
(Dollars in thousands, except per share data)
(unaudited)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| Reconciliation of adjusted gross margin | ||||||||||||||||
| GAAP gross margin | $ | 68,430 | $ | 60,934 | $ | 211,812 | $ | 179,108 | ||||||||
| Expense related to a flash flood event (1) | — | 543 | — | 4,308 | ||||||||||||
| Inventory valuation adjustment (2) | 1,584 | — | 1,584 | — | ||||||||||||
| Amortization of intangible assets and finance lease (3) | 677 | 336 | 1,313 | 1,164 | ||||||||||||
| Adjusted gross margin | $ | 70,691 | $ | 61,813 | $ | 214,709 | $ | 184,580 | ||||||||
| Reconciliation of adjusted earnings from operations | ||||||||||||||||
| GAAP earnings from operations | $ | 33,625 | $ | 32,513 | $ | 111,881 | $ | 93,681 | ||||||||
| Expense related to a flash flood event (1) | — | 543 | — | 4,308 | ||||||||||||
| Inventory valuation adjustment (2) | 1,584 | — | 1,584 | — | ||||||||||||
| Amortization of intangible assets and finance lease (3) | 7,975 | 6,207 | 19,840 | 19,025 | ||||||||||||
| Transaction and integration costs, ERP implementation costs, and unallocated legal fees (4) | 1,640 | 305 | 2,816 | 1,005 | ||||||||||||
| Adjusted earnings from operations | $ | 44,824 | $ | 39,568 | $ | 136,121 | $ | 118,019 | ||||||||
| Reconciliation of adjusted net earnings | ||||||||||||||||
| GAAP net earnings | $ | 25,249 | $ | 25,013 | $ | 83,961 | $ | 71,155 | ||||||||
| Expense related to a flash flood event (1) | — | 543 | — | 4,308 | ||||||||||||
| Inventory valuation adjustment (2) | 1,584 | — | 1,584 | — | ||||||||||||
| Amortization of intangible assets and finance lease (3) | 8,097 | 6,278 | 20,103 | 19,237 | ||||||||||||
| Transaction and integration costs, ERP implementation costs, and unallocated legal fees (4) | 1,640 | 305 | 2,816 | 1,005 | ||||||||||||
| Unrealized foreign currency gain on contingent consideration liability and net realized gain on foreign currency forward contracts (5) | (2,015 | ) | — | (2,527 | ) | — | ||||||||||
| Income tax adjustment (6) | (2,168 | ) | (2,164 | ) | (5,746 | ) | (6,886 | ) | ||||||||
| Adjusted net earnings | $ | 32,387 | $ | 29,975 | $ | 100,191 | $ | 88,819 | ||||||||
| Adjusted net earnings per common share - diluted | $ | 1.00 | $ | 0.92 | $ | 3.09 | $ | 2.72 | ||||||||
The following table sets forth a reconciliation of Net Income calculated using amounts determined in accordance with GAAP to EBITDA and to Adjusted EBITDA for the three and nine months ended September 30, 2022 and 2021.
Table 2
(unaudited)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| Net income - as reported | $ | 25,249 | $ | 25,013 | $ | 83,961 | $ | 71,155 | ||||||||
| Add back: | ||||||||||||||||
| Provision for income taxes | 5,836 | 7,072 | 24,012 | 20,932 | ||||||||||||
| Other expense | 2,540 | 428 | 3,908 | 1,594 | ||||||||||||
| Depreciation and amortization | 13,976 | 12,088 | 37,696 | 36,410 | ||||||||||||
| EBITDA | 47,601 | 44,601 | 149,577 | 130,091 | ||||||||||||
| Add back certain items: | ||||||||||||||||
| Non-cash compensation expense related to equity awards | 2,949 | 2,895 | 9,838 | 8,809 | ||||||||||||
| Expense related to a flash flood event (1) | — | 543 | — | 4,308 | ||||||||||||
| Inventory valuation adjustment (2) | 1,584 | — | 1,584 | — | ||||||||||||
| Transaction and integration costs, ERP implementation costs, and unallocated legal fees (4) | 1,640 | 305 | 2,816 | 1,005 | ||||||||||||
| Adjusted EBITDA | $ | 53,774 | $ | 48,344 | $ | 163,815 | $ | 144,213 | ||||||||
The following table sets forth a reconciliation of our GAAP effective income tax rate to our non-GAAP effective income tax rate for the three and nine months ended September 30, 2022 and 2021.
Table 3
(unaudited)
| Three Months Ended September 30, | ||||||||||||||||
| 2022 | Effective Tax Rate | 2021 | Effective Tax Rate | |||||||||||||
| GAAP Income Tax Expense | $ | 5,836 | 18.8 | % | $ | 7,072 | 22.0 | % | ||||||||
| Impact of ASU 2016-09 (7) | 214 | 491 | ||||||||||||||
| Adjusted Income Tax Expense | $ | 6,050 | 19.5 | % | $ | 7,563 | 23.6 | % | ||||||||
| Nine Months Ended September 30, | ||||||||||||||||
| 2022 | Effective Tax Rate | 2021 | Effective Tax Rate | |||||||||||||
| GAAP Income Tax Expense | $ | 24,012 | 22.2 | % | $ | 20,932 | 22.7 | % | ||||||||
| Impact of ASU 2016-09 (7) | 714 | 1,031 | ||||||||||||||
| Adjusted Income Tax Expense | $ | 24,726 | 22.9 | % | $ | 21,963 | 23.9 | % | ||||||||
The following table sets forth a reconciliation of net cash provided by operating activities to free cash flow for the three and nine months ended September 30, 2022 and 2021.
Table 4
(unaudited)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| Net cash provided by operating activities | $ | 41,620 | $ | 39,634 | $ | 96,881 | $ | 116,023 | ||||||||
| Capital expenditures and capitalized ERP implementation costs | (14,841 | ) | (8,559 | ) | (35,021 | ) | (22,106 | ) | ||||||||
| Free cash flow | $ | 26,779 | $ | 31,075 | $ | 61,860 | $ | 93,917 | ||||||||
| (1) Expense related to a flash flood event: Expenses related to a flash flood event at our Verona, Missouri manufacturing site are expensed in our GAAP financial statements. We believe that excluding these costs from our non-GAAP financial measures is useful to investors because such expense is inconsistent in amount and frequency causing comparison of current and historical financial results to be difficult. |
| (2) Inventory valuation adjustment: Business combination accounting principles require us to measure acquired inventory at fair value. The fair value of inventory reflects the acquired company's cost of manufacturing plus a portion of the expected profit margin. The non-GAAP adjustment to our cost of sales excludes the expected profit margin component that is recorded under business combination accounting principles. We believe the adjustment is useful to investors as an additional means to reflect cost of sales and gross margin trends of our business. |
| (3) Amortization of intangible assets and finance lease: Amortization of intangible assets and finance lease consists of amortization of customer relationships, trademarks and trade names, developed technology, regulatory registration costs, patents and trade secrets, capitalized loan issuance costs, other intangibles acquired primarily in connection with business combinations, an intangible asset in connection with a company-wide ERP system implementation, and one finance lease. We record expense relating to the amortization of these intangibles and finance lease in our GAAP financial statements. Amortization expenses for our intangible assets and finance lease are inconsistent in amount and are significantly impacted by the timing and valuation of an acquisition. Consequently, our non-GAAP adjustments exclude these expenses to facilitate an evaluation of our current operating performance and comparisons to our past operating performance. |
| (4) Transaction and integration costs, ERP implementation costs and unallocated legal fees: Transaction and integration costs related to acquisitions and divestitures are expensed in our GAAP financial statements. ERP implementation costs related to a company-wide ERP system implementation are expensed in our GAAP financial statements. Unallocated legal fees for transaction-related non-compete agreement disputes are expensed in our GAAP financial statements. Management excludes these items for the purposes of calculating Adjusted EBITDA and other non-GAAP financial measures. We believe that excluding these items from our non-GAAP financial measures is useful to investors because these are items associated with each transaction and are inconsistent in amount and frequency causing comparison of current and historical financial results to be difficult. |
| (5) Unrealized foreign currency gain on contingent consideration liability and net realized gain on foreign currency forward contracts: The unrealized foreign currency gain relates to the contingent consideration liability recorded in connection with Kappa acquisition and was recorded as other income in our GAAP financial statements. The net realized gain on foreign currency exchange forward contracts relates to four short-term foreign currency exchange forward contracts with JP Morgan Chase, N.A. in connection with the Kappa acquisition. These contracts did not qualify for hedge accounting and the net gain was recorded as other income in our GAAP financial statements. We believe that excluding these gains and losses from our non-GAAP financial measures is useful to investors because such income or expense are inconsistent in amount and frequency causing comparison of current and historical financial results to be difficult. |
| (6) Income tax adjustment: For purposes of calculating adjusted net earnings and adjusted diluted earnings per share, we adjust the provision for (benefit from) income taxes to tax effect the taxable and deductible non-GAAP adjustments described above as they have a significant impact on our income tax (benefit) provision. Additionally, the income tax adjustment is adjusted for the impact of adopting ASU 2016-09, “Improvements to Employee Share-Based Payment Accounting” and uses our non-GAAP effective rate applied to both our GAAP earnings before income tax expense and non-GAAP adjustments described above. See Table 3 for the calculation of our non-GAAP effective tax rate. |
| (7) Impact of ASU 2016-09: The primary impact of ASU No. 2016-09, "Improvements to Employee Share-Based Payment Accounting" ("ASU 2016-09"), was the recognition during the three and nine months ended September 30, 2022 and 2021, of excess tax benefits as a reduction to the provision for income taxes and the classification of these excess tax benefits in operating activities in the consolidated statement of cash flows instead of financing activities. |
FAQ
What were Balchem's Q3 2022 earnings results?
How much were Balchem's net sales in Q3 2022?
What is Balchem's future outlook after Q3 2022?
What is Balchem's adjusted EBITDA for Q3 2022?
How did Balchem's tax rate change in Q3 2022?
